 CAMBRIDGE, Mass.--BUSINESS WIRE--Sage Therapeutics NASDAQ: SAGE, a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating brain disorders, today announced that Mike Cloonan, Sages Chief Operating Officer, is leaving the company effective May 3, 2021 to pursue other opportunities. Mike has made significant contributions to Sage over the past four years. We extend our thanks for his leadership and wish him noth 